Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration: Experience of a community-based teaching hospital

HE WANG1,2, CYRIL D’CRUZ1, DAVID C. YAM1, LORIE M. DILLA1 and PATRICIA TSANG1

1Department of Laboratory Medicine and Pathology, Newark Beth Israel Medical Center, Barnabas Health System, Newark, New Jersey 07112; 2Department of Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA

Received September 4, 2013; Accepted May 14, 2014

DOI: 10.3892/mmr.2014.2533

Abstract. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure. This procedure is useful for nodal staging of lung cancer and evaluating mediastinal lymphoma and granuloma. The present study was a retrospective analysis of our experience when EBUS-TBNA was initially implemented. A total of 112 lymph nodes/masses (51 patients) were divided into two groups: The first and second 8 months. In the first group, 33 lymph nodes/masses (16 patients) were biopsied and tumor diagnoses were made in 9% of the cases (three lymph nodes/masses). The material was adequate to produce a cell block for microscopic analysis in 42% of cases. Subsequent tissue diagnoses were available in 50% of cases. Only one of the three malignant EBUS-TBNA diagnoses (33%) was confirmed by histological examination. In the second 8 months, 79 lymph nodes (35 patients) were sampled. Tumor/granuloma diagnoses were achieved in 27% of the cases (21 nodes) (P=0.045 versus the first 8 months) and the obtained material was adequate for producing a cell block in 90% of cases (P<0.001 versus the first 8 months). Corresponding tissue diagnoses were available in 28% of cases. Correlation of EBUS-TBNA and histological examination for tumor/granuloma diagnosis was 100% (12/12, P=0.029 versus the first 8 months). Immunostains in the cell blocks indicated that all the metastatic adenocarcinomas were thyroid transcription factor-1 (TTF-1)+ and p63+, and that all squamous cell carcinomas were TTF-1-,p63+ and cytokeratin 5/6 (CK5/6)+. Eight granulomata were identified, of which five were positive for Acid-Fast Bacilli (AFB) stain and confirmed by culture or tissue biopsy. The remaining three granulomata were AFB-negative. EGFR/KRAS mutation analysis was conducted in cell blocks of five adenocarcinomas, of which all provided sufficient diagnostic material. The findings showed a steep learning curve when EBUS-TBNA was first adopted, reflected by an increased rate of tumor/granuloma diagnoses as well as an improved sample yield for cell block preparation in the second 8 months. TTF-1, p63 and CK5/6 were useful biomarkers for distinguishing metastatic lung carcinomas.

Introduction

The assessment of mediastinal adenopathy by non-invasive imaging modalities, such as computed tomography (CT) and positron emission tomography (PET), is a clinically useful technique. However the accuracy of these imaging modalities is usually insufficient to distinguish between benign and malignant lymph nodes for the purpose of determining subsequent treatment options. The sensitivity of CT and PET is between 60 and 85%, while the specificity is between 79 and 90% (1,2). In current practice, pathological examination is necessary for PET-positive lymph nodes for mediastinal staging of lung cancer. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that was approved by the US Food and Drug Administration in March 2006. The effectiveness of EBUS-TBNA in mediastinal staging of lung carcinoma and in diagnosing central and peripheral lung masses, mediastinal involvement of lymphoma and isolated mediastinal lymphadenopathy has been previously reported (1-3). In addition to impressive sensitivity and specificity, EBUS-TBNA may be performed in the ambulatory care setting under sedation, the procedure is cost-effective, accessible to more lymph node stations, with less post-procedural complications (2,3). Previous studies emphasized the importance of close communication between bronchoscopists, radiologists and pathologists for the success of EBUS-TBNA procedure (4,5). However, the majority of these published data are from large tertiary medical centers with advanced stages of disease and greatly enlarged lymph nodes (6,7). Conclusions from these studies may not represent the typical patient population in general practice.
The present retrospective study reviewed our initial experience with EBUS-TBNA since its first introduction into the Newark Beth Israel Medical Center (Newark, NJ, USA), covering a period of 16 months. This study additionally discussed the efficient use of immunostaining with the limited material in cell blocks.

Materials and methods

Patients. All patients with mediastinal or hilar lymphadenopathy or a mediastinal mass referred for EBUS-TBNA in the Newark Beth Israel Medical Center between January 2011 and April 2012 were enrolled in this study. This study was approved by the institutional Ethics Committee, and followed international and national regulations. All patients provided informed consent. The primary indications for TBNA were the sampling and diagnosis of enlarged lymph nodes of unknown origin and lung cancer staging. A chest radiograph was routinely performed in these patients, and selected patients also underwent a CT scan of the chest (plain and/or contrast enhanced).

EBUS-TBNA. Conventional flexible bronchoscopy (BF-7160 bronchoscope; Olympus, Ltd., Tokyo, Japan) was first performed by standard methodology to examine the tracheobronchial tree, followed by EBUS-TBNA using the new ultrasound biopsy bronchoscope (XBF-UC260F-OL8; Olympus, Ltd.). Both bronchoscopy procedures were performed by the same operator. Endobronchial ultrasound was performed using a prototype linear array ultrasonic bronchoscope. The instrument, similar to a standard bronchoscopic videoscope, had an outer diameter of 6.9 mm, a 2.0-mm instrument channel and 30° oblique forward viewing optics. An electronic convex array ultrasound transducer was mounted at the distal tip and was covered by a water inflatable balloon sheath. Scanning was performed at a frequency of 7.5 MHz and with a penetration of 50 mm. The angle of view was 90° and the direction of view was 30° forward oblique.

A dedicated 21/22-gauge needle (XNA-202C; Olympus, Ltd.) was developed to perform the TBNA. The needle was also equipped with a stylet that was withdrawn subsequent to passing the bronchial wall, avoiding contamination during the TBNA. The needle was mounted at the biopsy channel inlet of the endoscope prior to puncture and the needle exited the outer covering of the insertion tube at 20°. The needle was visualized through the optics and on the ultrasound image.

Biopsy procedure. The probe was introduced through the mouth and vocal cords into the main carina. The balloon was partially inflated (0.3–0.5 ml water) and the regional lymph node stations of the middle mediastinum and hilar regions (stations 2, 3, 4, 7, 10 and 11) were systematically imaged and measured (short-axis diameter) during the slow withdrawal and rotation of the transducer. Fine needle aspiration (FNA) was performed by passing the dedicated prototype 21/22-gauge needle through the airway wall and into the lymph nodes under real-time ultrasound guidance. Needle punctures were performed using the jabbing method. Integrated power Doppler ultrasound was used to visualize and avoid potentially intervening vessels immediately prior to needle puncture.

One to four mediastinal lymph nodes were sampled per patient, with a maximum of seven passes/node. EBUS-TBNA aspirates were expelled from the needle by either blowing air through a 20-ml syringe or by reinsertion of the stylet. A portion of the aspirates was smeared on glass slides, air-dried and immediately stained with a Diff-Quick (DQ) staining kit (NC9943455; Fisher Scientific, Pittsburgh, PA, USA). Another portion of the aspirates was also smeared on glass slides and immediately placed into 95% ethanol for Papanicolaou (Pap) staining. The remaining specimen, collected subsequent to rinsing with Cytorich Red (05NG-00003; BD Diagnostics, Burlington, NC, USA), was collected in a Cytorich-containing cup and processed for ThinPrep (BD PrepStain Slide Processor; BD Diagnostics) and cell block evaluation. The last two to five aspirates of EBUS-TBNA specimens/site were collected and placed directly into Cytorich Red for additional studies, including cell block preparations. These were not examined on-site. The sediment obtained from the Cytorich Red cup was processed in paraffin blocks, and the histological slides were stained with hematoxylin-eosin. Up to five passes/lymph node were collected, smeared and examined on-site. However, the procedure was terminated earlier if a tumor/granuloma or other specific diagnoses were reached.

Acid-Fast Bacilli (AFB) and Gomori-Grocott's methenamine silver stains were performed in the cell block slides of all samples with granuloma. In certain cases, culture of Mycobacterium tuberculosis was also conducted. Immunostaining was conducted at the discretion of the attending pathologists.

Final diagnosis. Lymph node aspirates obtained by EBUS-TBNA were considered to be representative if two lymphohistiocytic aggregates or five groups of lymphocytes (>20 cells/group) were identified. Aspirates containing other cellular material that resulted in a specific diagnosis (carcinoma, thymoma, granulomas or lymphoma) were also considered representative (8).

The diagnosis of tumors from EBUS-TBNA was considered final. When a granuloma was identified, a diagnosis of mycobacteria infection was explored by AFB stain and/or bacterial culture. The final diagnosis of sarcoidosis was based on clinical and radiological suspicion, tissue confirmation of noncaseating granulomas and a follow-up period, subsequent to which similarly presenting diseases, such as lung cancer, lymphoma or tuberculosis, could be excluded.

Additional tissue examination of a particular patient was based wholly on clinical suspicion/treatment decisions. Whenever possible, the tissue diagnosis was compared with that derived from the EBUS-TBNA aspirates. Reactive lymph nodes diagnosed by biopsy were considered true negative results; tumors (including lymphoma) and sarcoidosis diagnosed by biopsy/clinal follow-up were considered true positive results.

Statistical methods. The primary end-point of the study was the percentage of biopsy specimens obtained that contained lymphocytes/lymphohistiocytic aggregates. The secondary end-point was the percentage of confirmed diagnoses made possible with EBUS-TBNA. Diagnostic sensitivity, specificity and accuracy were calculated using the standard definitions.
The proportion of true positive results, true negative results and all correct results, respectively. Reactive lymph nodes diagnosed by biopsy were considered true negative results; tumors (including lymphoma) and sarcoidosis diagnosed by biopsy/clinical follow-up were considered true positive results. The unit of analysis was the patient.

Results

Patient demographics. EBUS-TBNA was performed in all 51 patients; the majority of the patients (29 patients, 57%) were of African-American descent. The average age of the patients was 57.1 years. On-site smear preparation and interpretation, as well as cell block preparation, were attempted in all patients.

Learning analysis. The retrospective analysis showed that, in the first 8 months, tumor/granuloma diagnoses were made in only 9.1% of cases (three nodes/masses, one lymphoma, one thymoma and one squamous cell carcinoma (SCC)) while specimens that were negative for malignant cells comprised 84.9% of cases. By contrast, tumor/granuloma diagnoses were achieved in 27% of cases in the second 8 months (21 nodes, 10 pulmonary adenocarcinoma, two SCCs, one non-classified poorly differentiated carcinoma and eight granulomas) (P=0.045 versus the first 8 months) (Table I).

In the first 8 months, cell blocks could be made in only 14 out of 33 lymph nodes/masses (42.4%) due to poor cellularity in the remaining cases. By contrast, cell blocks were available in 71 out of 79 cases in the second 8 months (90.0%) (P<0.001 versus the first 8 months). Smear preparations (including DQ, Pap smear and thin preparations) were deemed as non-diagnostic samples in two out of 33 nodes/masses (6.1%) in the first 8 months of the EBUS-TBNA procedure; in the second 8 months the node-diagnostic smear samples decreased to three out of 79 nodes (3.8%) (P=0.46 versus the first 8 months) (Table I).

Correlation between EBUS-TBNA and biopsy. In the first 8 months, tissue diagnoses were available for 17 nodes/masses. Fourteen of the diagnoses were benign/reactive lymph nodes, and the corresponding FNA diagnoses were 100% matched with the tissue diagnoses. There were three tumor diagnoses by tissue examination: SCC, thymoma and B-cell lymphoma. The corresponding FNA diagnoses were SCC, atypical lymphoid tissue and suspicious for thymoma, respectively. In the second 8 months, tissue diagnoses were available for 23 nodes/masses, including three adenocarcinomas, two SCCs and seven granulomas, representing 33.0, 100 and 88.0% of the total EBUS-TBNA case numbers in their respective category, respectively. The eight benign/reactive diagnoses of the biopsy showed 100% concordance with the FNA diagnoses. There were 12 tumor/noncaseating granuloma diagnoses by tissue examination, three adenocarcinomas, two SCCs and eight noncaseating granulomas. The corresponding FNA diagnoses were 100% matched with the tissue diagnoses (Figs. 1 and 2). The sensitivity, specificity and accuracy in the first 8 months were 33.0, 100 and 88.0%, respectively. The sensitivity, specificity and accuracy in the second 8 months were all 100% (Fig. 3).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>First 8 months, n/total n (%)</th>
<th>Second 8 months, n/total n (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell block</td>
<td>14/33 (42)</td>
<td>71/99 (90)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tumor/granuloma</td>
<td>3/33 (9)</td>
<td>21/79 (27)</td>
<td>0.045</td>
</tr>
<tr>
<td>Non-diagnostic smears</td>
<td>2/33 (6)</td>
<td>3/79 (4)</td>
<td>0.460</td>
</tr>
<tr>
<td>FNA versus tissue correlation for tumor/granuloma</td>
<td>1/3 (33)</td>
<td>12/12 (100)</td>
<td>0.029</td>
</tr>
</tbody>
</table>

FNA, fine needle aspiration.

Immunohistochemical and genetic prognostic marker analysis. Immunohistochemical stains were performed in cell blocks of 10 tumor samples: Seven adenocarcinomas and three SCCs. All of the adenocarcinomas were thyroid transcription factor-1 (TTF-1)-positive with negative or very focal p63 stains; all of the SCCs were TTF-1-negative and p63- and cytokeratin 5/6 (CK5/6)-positive (Figs. 1 and 2).

EGFR/KRAS mutation analysis was conducted in the cell blocks of five adenocarcinomas upon the request of the treating physicians. All of the cell blocks contained sufficient material for analysis; one case showed a mutation in exons 18-21 of EGFR, two cases revealed KRAS mutations at codons 12 and 13 and two cases exhibited no EGFR or KRAS mutation.

Complications. No sedative drugs were administered to any patients during the procedure. No major complications, such as pneumothorax, mediastinal emphysema or bleeding from ruptured major vessels in the mediastinum, were noted during the procedure or in the follow-up period.

Discussion

This study is not the first to report a learning curve following the initial application of EBUS-TBNA in a medical center (7). Groth et al (9) suggested that the learning curve for EBUS-FNA for thoracic surgeons is ~10 procedures. Sun et al (10) reported that, following the initial five procedures, the sensitivity of EBUS-TBNA for diagnosing lung cancer should be ≥90% for pulmonologists experienced in bronchoscopy. However, the majority of these reports are from tertiary medical centers with a selected patient population. At least one recent study has suggested that EBUS-TBNA results from these centers may not be entirely representative in a more general patient population in routine care (11). The present study was conducted in an urban community medical center, with the patient population including 57% African-Americans and a significant number of patients who were human immunodeficiency virus (HIV)-positive. In this medical center, diagnoses of 13 out of the first 16 patients were benign (no evidence of malignant cells). Four of these 13 patients underwent biopsy/resection and 100% agreement between TBNA and the histological diagnoses was achieved. The first EBUS-TBNA diagnosis of metastatic pulmonary carcinoma was made in the 16th patient, which was confirmed later by an evaluation of a histological biopsy.
Figure 1. Adenocarcinoma of the lung (magnification, x 400). Insert: thyroid transcription factor-1 immunostain.

Figure 2. Squamous cell carcinoma (magnification, x 400). Insert: p63 immunostain.

Figure 3. Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration. ms, months.
sample. The two misclassified tumors (one thymoma and one B-cell lymphoma) occurred in the third and eighth patients, respectively. It is important to note that both false positive and false negative results have been reported for EBUS-TBNA, even in centers experienced in this procedure (12). Limited cellularity is clearly a contributing factor to the difficulty in classification, as the aspirated material from one of three tumors was not sufficient to make a cell block (the thymoma case); the material from another patient (the lymphoma case) was not sufficient to run flow cytometry. In the first 8 months of this study, cell blocks were made in only 42% of cases due to poor cellularity. Rapid on-site evaluation (ROSE) and effective communication with the bronchoscopists are therefore critical to guarantee sufficient cellularity and achieve a correct diagnosis. As suggested by Monaco et al (13), the presence of cytologists also allows the appropriate triage of material for ancillary studies, including tissue culture, flow cytometry, immunostaining and molecular studies. At the initial stage of the EBUS-TBNA procedure, a lack of standardization of the ROSE procedure and the different expectations from bronchoscopists, pathologists and radiologists may also contribute to the suboptimal early results.

The tumor/granuloma diagnoses were significantly increased to 27% in the second 8 months of the study. Sufficient diagnostic material in the majority of cases (cell blocks in 90% of cases) and effective communication with bronchoscopists (ROSE) were necessary for this improvement. Other factors, including accurate positioning of the probe into the lesion following further practice (14), may also have influenced the improvement. The pattern of the learning curve for this EBUS-TBNA is similar to that of previous reports (5,8,9,15). However, significant differences between our results and previous reports were also noted. Firstly, the tumor diagnosis rate in the cohort in the second 8 months was 16%, less than that of previous reports (~45%) (2,5). Secondly, the rate of sarcomatoid carcinoma was 10%, which was higher than that reported in previous studies (~5%). In addition, the malignancy rate in the second 8 months was 71%, which was higher than that reported in previous studies (~35%). The majority of these differences may be attributed to different patient populations due to the following reasons: i) There was no significant increase in the tumor/granuloma malignancy diagnostic rate in the center, even during the most recent months (after the second 8 months); ii) a recent study using a population under routine care also achieved a similar tumor/sarcomatoid carcinoma diagnostic rate of ~27% (11); iii) a significant number of patients in our medical center immunosuppressive (patients who had undergone heart, lung or renal transplantations and patients with HIV) (16). Rates of infection and associated mediastinal reactive lymphadenopathy were therefore expected to be higher than those in previously reported patient populations.

With the advances in personalized chemotherapy, the subclassification of non-small cell lung carcinomas has become necessary. The EGFR inhibitors erlotinib and gefitinib are most efficacious in tumors with EGFR mutation, which are predominantly adenocarcinomas (17). Similarly, the folate inhibitor pemetrexed is currently the most effective drug treatment for adenocarcinoma, but not SCC (18). An inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, targets tumors with EML4-ALK fusion, which occurs predominantly in adenocarcinoma (19). One caveat of the EBUS-TBNA specimen is the limited diagnostic material, which requires the strategic use of antibodies rather than screening with a panel of antibodies. It is noteworthy that in the present analyzed cohort, only two or three antibodies were required to differentiate the non-small cell carcinomas of the pulmonary origin. In this study, immunohistochemical stains were performed in the cell blocks of seven metastatic carcinomas of the pulmonary origin (four adenocarcinomas and three SCCs). All the adenocarcinomas were TTF-1-positive with negative or very focal p63 stains and the SCCs were TTF-1-negative and extensively positive for p63 and CK5/6. These results closely correlated with the conclusions by Mukhopadhyay (20) from studies of small histology biopsy samples. The analysis of genetic mutations to EGFR, Ras and ALK is required for the effective treatment of pulmonary adenocarcinoma, either for the selection of chemotherapy or for the subclassification of tumors and possibly for the assessment of therapeutic and prognostic markers. TTF-1, p63 and possibly CK5/6 are usually sufficient to differentiate SCC from adenocarcinoma of the lung.

References


